The study determined that the combination of anti-PD-1 immunosuppressant, CCR2/CCR5 antagonists and RT (3 × 8 Gy) was found to inhibit the infiltration of M2-type TAMs, Tregs and MDSCs, and this combination had better anti-tumor effects. Here, CCR5 is linked to neoplasm.